WILMINGTON, DE — AstraZeneca is advancing its global efforts to transform cancer care by presenting pivotal data from its oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, set for May 30 to June 3, 2025. With more than 80 abstracts featuring 20 approved and investigational medicines, AstraZeneca continues to solidify its leadership position in innovative cancer treatments.
Three key trials, including plenary sessions for SERENA-6 and MATTERHORN, as well as the DESTINY-Breast09 trial, exemplify the company’s progress in reshaping outcomes across various types of cancer.
SERENA-6 Trial
The Phase III SERENA-6 trial evaluated camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), in combination with cyclin-dependent kinase (CDK) 4/6 inhibitors for advanced HR-positive, HER2-negative breast cancer. This marks the first positive trial using circulating tumor DNA to inform treatment modifications in the first-line setting.
“For camizestrant, SERENA-6 is the first pivotal Phase III trial to use circulating tumor DNA to inform a treatment switch, pioneering this technology in the first-line setting to delay disease progression,” said Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca.
MATTERHORN Study
The MATTERHORN trial investigated perioperative use of IMFINZI® (durvalumab) alongside FLOT chemotherapy in patients with early-stage gastric and gastroesophageal junction cancers. The findings demonstrate the potential of immunotherapy to improve outcomes in the early stages of cancer, where effective treatment is critical to achieving curative results.
“The MATTERHORN data for perioperative IMFINZI in gastric and gastroesophageal junction cancers are a further example of our successful strategy to move immunotherapy into early stages of cancer where cure is the treatment goal,” said Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Haematology Business Unit.
DESTINY-Breast09 Trial
The DESTINY-Breast09 Phase III trial assessed the efficacy of ENHERTU® (fam-trastuzumab deruxtecan-nxki) combined with pertuzumab in HER2-positive metastatic breast cancer. It is the first study in over a decade to demonstrate superiority over the standard-of-care treatment across a broad patient population in this setting.
Galbraith remarked, “DESTINY-Breast09 for ENHERTU in combination with pertuzumab is the first trial in more than a decade to demonstrate superiority over first-line standard of care across a broad HER2-positive metastatic patient population.”
Collaborations and Broader Innovations
AstraZeneca’s pipeline also includes groundbreaking trials such as the NeoADAURA and TROPION-Lung02 studies, which highlight advancements in lung cancer treatment. Collaborative efforts with Daiichi Sankyo, Merck & Co., Inc., and HUTCHMED further underscore AstraZeneca’s dedication to accelerating progress across oncology.
Fredrickson added, “This is the seventh consecutive year AstraZeneca medicines will be featured in an ASCO plenary session, an extraordinary milestone which underscores the strength of our industry-leading oncology portfolio and pipeline across many types of cancer.”
By leveraging leading-edge therapies and global partnerships, AstraZeneca aims to revolutionize cancer treatment and bring renewed hope to patients worldwide.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.